# OnCo record glioma-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/glioma-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "glioma-signalling" ;
  schema:name "Glioma (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05214"@en, "Glioma"@en ;
  schema:description "This KEGG map shows the two genetic roads to glioblastoma: primary tumours amplify EGFR and lose PTEN and p16, secondary tumours from lower-grade astrocytomas over-express PDGF and CDK4 and lose TP53 and RB. It explains why growth-factor and cell-cycle drugs are the main targeted options in brain tumours, and why paediatric low-grade gliomas with BRAF changes respond to MAPK inhibitors."@en ;
  schema:url <https://onco.cc/pathways/glioma-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05214>, <https://doi.org/10.1038/nrdp.2015.17> ;
  onco:related <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/idh-2hg/> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/pdgfra/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/mdm2/>, <https://onco.cc/targets/idh/>, <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/tovorafenib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/selumetinib/>, <https://onco.cc/drugs/mirdametinib/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/lomustine/> ;
  onco:pathways <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/idh-2hg/>, <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-weller-nat-rev-dis-primers/> .